吲哚硫酸通过芳香烃受体上调肝脏P-糖蛋白表达与活性
该研究探讨尿毒症毒素吲哚硫酸(IS)是否通过芳香烃受体改变肝脏药物转运体表达。体外HepG2细胞中IS经芳香烃受体通路上调ABCB1编码的P-糖蛋白表达与活性,生理浓度人白蛋白未消除该效应;两种CKD小鼠模型肝脏Abcb1a特异性上调;109例伴CKD的心脏或肾移植受者中,血清IS较高者需更高环孢素剂量达到目标血药浓度。
要点
- IS经芳香烃受体上调肝细胞P-糖蛋白表达与活性
- CKD小鼠肝Abcb1a特异性上调,与IS蓄积相关
- 血清IS较高者环孢素需求量增加,提示肝清除增强
核心结论
- 尿毒症毒素如IS可通过影响药物转运体改变CKD患者的非肾性药物清除。
研究设计与样本
- 体外HepG2细胞实验、两种CKD小鼠模型及109例伴CKD的心脏或肾移植受者观察性分析。
主要发现
- IS增加HepG2细胞中ABCB1编码的P-糖蛋白表达与活性,且不改变其他所测转运体表达;该效应依赖芳香烃受体通路。
- 生理浓度人白蛋白存在时IS的效应未被消除。
- 两种CKD小鼠模型中肾功能下降伴血清IS蓄积,肝脏Abcb1a特异性上调。
- 109例伴CKD的心脏或肾移植受者中,血清IS较高者需更高环孢素剂量达到目标血药浓度,且独立于肾功能。
关键数值与推荐
- 所测转运体包括SLC10A1、SLC22A1、SLC22A7、SLC47A1、SLCO1B1、SLCO1B3、SLCO2B1、ABCB1、ABCB11、ABCC2、ABCC3、ABCC4、ABCC6和ABCG2;仅ABCB1/P-gp改变。
- 体外实验使用人肝癌细胞HepG2,培养液中含生理浓度人白蛋白。
- 伴CKD的心脏或肾移植受者共109例,以环孢素为目标P-gp底物。
临床怎么用
- CKD患者使用P-糖蛋白底物(如环孢素)时,可关注血清IS水平对非肾性清除及剂量的潜在影响。
局限性
- 原文摘要未报告IS具体浓度、环孢素剂量数值及小鼠模型细节。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In patients with CKD, not only renal but also, nonrenal clearance of drugs is altered. Uremic toxins could modify the expression and/or activity of drug transporters in the liver. We tested whether the uremic toxin indoxyl sulfate (IS), an endogenous ligand of the transcription factor aryl hydrocarbon receptor, could change the expression of the following liver transporters involved in drug clearance: SLC10A1, SLC22A1, SLC22A7, SLC47A1, SLCO1B1, SLCO1B3, SLCO2B1, ABCB1, ABCB11, ABCC2, ABCC3, ABCC4, ABCC6, and ABCG2 We showed that IS increases the expression and activity of the efflux transporter P-glycoprotein (P-gp) encoded by ABCB1 in human hepatoma cells (HepG2) without modifying the expression of the other transporters. This effect depended on the aryl hydrocarbon receptor pathway. Presence of human albumin at physiologic concentration in the culture medium did not abolish the effect of IS. In two mouse models of CKD, the decline in renal function associated with the accumulation of IS in serum and the specific upregulation of Abcb1a in the liver. Additionally, among 109 heart or kidney transplant recipients with CKD, those with higher serum levels of IS needed higher doses of cyclosporin, a P-gp substrate, to obtain the cyclosporin target blood concentration. This need associated with serum levels of IS independent of renal function. These findings suggest that increased activity of P-gp could be responsible for increased hepatic cyclosporin clearance. Altogether, these results suggest that uremic toxins, such as IS, through effects on drug transporters, may modify the nonrenal clearance of drugs in patients with CKD.
引用
- Santana Machado T, Poitevin S, Paul P, et al. Indoxyl Sulfate Upregulates Liver P-Glycoprotein Expression and Activity through Aryl Hydrocarbon Receptor Signaling. J Am Soc Nephrol. 2017. PMID: 29222397. doi:10.1681/ASN.2017030361
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。